Archives
-
URB597: Causal Mapping of FAAH Signaling
2026-09-29
URB597 (KDS-4103) is a selective FAAH inhibitor for testing how anandamide metabolism shapes endocannabinoid signaling. This article presents a causal, assay-centered framework that separates FAAH-dependent mechanisms from the broader pharmacology of cannabidiol in pain and neuroinflammation research.
-
NADH Reprograms E. tarda Antibiotic Killing
2026-09-28
A 2024 Virulence study shows that exogenous NADH can reprogram Edwardsiella tarda metabolism, increase ATP availability, and strengthen the bactericidal activity of neomycin. The work supports metabolic supplementation as an antibiotic-adjuvant strategy while identifying important limits for translation beyond bacterial culture systems.
-
Vincristine Sulfate: From Tubulin to Translation
2026-09-28
Vincristine sulfate offers translational researchers a defined way to perturb microtubule dynamics and investigate tumor-cell response. This perspective connects its mechanism and model-specific evidence to practical study design, while distinguishing useful hypotheses from conclusions the data do not yet support.
-
Synthetic Receptor Microglia for Amyloid-β Clearance
2026-09-27
A 2025 mouse study reports a synthetic efferocytic receptor that reprograms microglia to recognize and clear amyloid-β while limiting inflammatory signaling. The work combines an amyloid-targeting binding domain with efferocytosis-associated signaling and microglia-directed mRNA delivery, offering a distinct preclinical strategy from conventional antibody-mediated clearance.
-
Cy5-UTP for RNA Probes: Workflow & Troubleshooting
2026-09-26
Use Cy5-UTP to make fluorescent RNA probes for FISH and related assays, with a practical workflow for balancing signal against transcription yield. The guide also shows how to apply labeled probes to MALAT1-focused experiments while keeping fluorescence imaging distinct from the RNA–protein assays needed to test TDP-43 binding.
-
Cy5-labeled mRNA for Macrophage Delivery Assays
2026-09-25
Separate cellular uptake from successful translation with a dual-readout reporter in macrophage gene-delivery experiments. Pair Cy5 tracking with EGFP expression to compare formulations, while treating fluorescence as an assay signal—not proof of intact cytosolic mRNA or therapeutic efficacy.
-
Lypressin Acetate: Assays, Workflows & Troubleshooting
2026-09-25
Use Lypressin acetate to probe vasopressin-receptor signaling, antidiuretic biology, and vasoconstriction research with workflows tailored to each question. This guide separates established product specifications from proposed assay starting conditions and explains why exploratory SARS-CoV-2 RdRp findings need independent validation.
-
Necrosulfonamide and the Logic of Necroptosis
2026-09-24
A translational framework for using Necrosulfonamide to test whether MLKL-dependent membrane disruption contributes to injury—without confusing downstream pathway inhibition with proof of upstream mechanism or therapeutic efficacy.
-
PR-619 and the Logic of DUB Pathway Dissection
2026-09-24
PR-619 offers a reversible, cell-permeable way to perturb cysteine-dependent deubiquitylating enzymes and examine ubiquitin-dependent protein homeostasis. This article explains how to interpret that perturbation, design stronger cell-based studies, and apply quality-by-design thinking without overstating what a broad-spectrum inhibitor can establish.
-
Cabozantinib (XL184) in RCC Adaptation Studies
2026-09-23
Use Cabozantinib to compare immediate kinase-pathway suppression with the signaling and motility changes that emerge during prolonged drug exposure in renal cell carcinoma models. This workflow connects phosphoproteomics to migration and invasion assays, with practical controls for dose selection, solvent handling, and interpretation.
-
Dantrolene Sodium Salt in CRISPR Assays
2026-09-23
Dantrolene sodium salt is examined as a mechanistic calcium-signaling control for CRISPR DNA-repair experiments rather than as a presumed DNA-repair inhibitor. This article connects ryanodine receptor pharmacology with assay interpretation, viability normalization, and translational pancreatitis research.
-
SCH772984: ERK1/2 Inhibition in Radioresistance
2026-09-22
Explore how SCH772984, a selective ERK1/2 inhibitor, can clarify the MAPK contribution to ferroptosis control and radioresistance. This article translates mechanistic findings from nasopharyngeal carcinoma research into mutation-aware, causally rigorous assay strategies.
-
EV-Based Degradation of Multiple Extracellular Proteins
2026-09-22
This reference study identifies autophagy-mediated lysosomal degradation as the principal route for extracellular vesicle clearance and converts that biology into a modular EV-based targeted protein degradation platform. The engineered system degraded extracellular TNF-α and IL-1β without requiring receptors on target cells and showed anti-inflammatory activity in rat and goat models of intervertebral disc degeneration.
-
BHPF Inhibits GPER in Neuroblastoma Cells
2026-09-21
A 2024 Environmental Science & Technology study identifies fluorene-9-bisphenol (BHPF) as a direct inhibitor of G protein-coupled estrogen receptor 1 (GPER), linking receptor binding to altered calcium signaling and neuroblastoma-cell toxicity. By integrating molecular dynamics, receptor-residue validation, gene knockout, and cellular assays, the work provides a mechanistic framework for evaluating BHPF as an endocrine-disrupting contaminant.
-
Tubastatin A: HDAC6 Inhibitor Workflow Guide
2026-09-21
Tubastatin A enables selective HDAC6 inhibition with practical readouts spanning α-tubulin acetylation, regulated cell death, inflammation, and myocardial injury. This workflow guide translates porcine cardiac-arrest evidence into controlled cell, tissue, and translational assay strategies while emphasizing dosing, vehicle, and target-engagement controls.